A huge amount of data obtained during last 30 years in multiple translational works allowed both to break particular tumor types into subgroups based on molecular markers but also to create pan-tumor subgroups based on particular markers. These evidence suggest the new approach to diagnostic and treatment algorithms should be implemented. Despite the rarity of some molecular markers the possibility of their presence must be kept in mind in order to achieve optimal results in patient’s treatment.